- Celltrion’s Q4 operating profit was 196.40 billion won, significantly below analyst estimates of 262.36 billion won, yet a substantial increase from the previous year’s 18.42 billion won.
- Net profit for Q4 was 236.65 billion won, close to the estimate of 237.17 billion won, and a noticeable rise from 1.05 billion won in the previous year.
- Sales in Q4 reached 1.06 trillion won, surpassing the estimate of 1.02 trillion won and more than doubling the previous year’s 382.60 billion won.
- For the full year 2024, Celltrion’s operating profit stood at 492.02 billion won, marking a 24% decrease year-over-year.
- Annual sales in 2024 reached 3.56 trillion won, reflecting an impressive 63% increase compared to the previous year.
- The company’s net profit for 2024 was 422.69 billion won, down by 21% from the previous year.
- Analyst recommendations for Celltrion include 25 buy ratings, 2 holds, and 1 sell.
Celltrion Inc on Smartkarma
Analysts on Smartkarma are closely following Celltrion Inc with differing perspectives. Douglas Kim‘s report titled “Celltrion: Meaningful Increase in Cash and Stock Dividends” highlights the company’s announcement of a significant increase in dividends. Shareholders will receive a stock dividend of 0.05, marking a 150% increase from the average dividend per share over the past three years, along with a cash dividend of 750 won. This move is likely to boost investor confidence in Celltrion.
On the positive side, Tina Banerjee‘s analysis “Celltrion Inc (068270 KS): Record High Sales in 3Q; Pipeline Progress Entails Long-Term Growth” emphasizes the company’s impressive 31% year-over-year revenue growth in the third quarter of 2024, driven by the success of new products. Despite maintaining a strong sales guidance for 2024 and expecting continued margin improvement, the company’s long-term growth prospects seem promising. However, Avien Pillay‘s report raises concerns in “Celltrion Inc (068270 KS)– Is the Sell-Side’s Bullishness Justified?” suggesting that Celltrion’s optimistic guidance may lead to an expensive valuation, cautioning against overestimating the company’s potential in the competitive biosimilar market.
A look at Celltrion Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 2 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 2.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts at Smartkarma have assessed Celltrion Inc‘s long-term outlook using their proprietary Smart Scores system. With moderate scores across the board, the company seems to have a balanced standing in key areas. Celltrion Inc has received a score of 2 for both its value and dividend factors, indicating average performance in these aspects. The growth and resilience scores, also at 2, suggest a stable growth trajectory and a reasonable level of resilience in challenging market conditions. Moreover, the momentum score of 3 implies a promising trend in the company’s performance in the near future.
Celltrion Inc, known for producing and selling biosimilar products while offering consignment processing services, primarily focuses on their leading product, Abatacept, used in the treatment of arthritis. The company’s overall Smart Scores paint a picture of a firm with a steady outlook, exhibiting potential for gradual growth and relative stability amidst market fluctuations. Investors may find Celltrion Inc an interesting prospect for a long-term investment strategy given its balanced performance indicators across various key factors.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
